A practical reference on Dual agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-11 and is reviewed periodically as new material appears.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
== Function == The protein encoded by this gene belongs to the family of G-protein coupled receptors, that are preferentially activated by adenosine and uridine nucleotides. This gene is moderately expressed in undifferentiated HL60 cells, and is located on both chromosomes X and Y.
Furthermore, loss-of-function mutations in the PCSK9 gene result in lower levels of LDL and protection against cardiovascular disease. In addition to its lipoprotein synthetic and pro-atherosclerotic effects, PCSK9 is involved in glucose metabolism and obesity, regulation of re-absorption of sodium in the kidney which is relevant in hypertension. Furthermore, PCSK9 may be involved in bacterial or viral infections and sepsis. In the brain the role of PCSK9 is still controversial and may be either pro-apoptotic or protective in the development of the nervous system. PCSK9 levels have been detected in the cerebrospinal fluid at a 50–60 times lower level than in serum.
== Characters == Erasmas (nickname "Raz"): The protagonist of Anathem; a Decenarian fraa from the Concent of Saunt Edhar. The neglected son of a lower-class family, he was collected by the concent at the age of eight. Orolo: A Decenarian fraa from the Concent of Saunt Edhar. He is an eminent cosmographer and Erasmas's mentor at the concent. He is banished for using forbidden technology to observe the alien ship in violation of the Discipline's isolation requirements. He dies while recovering the alien body from Orithena, and is canonized as a Saunt for his sacrifice. Arsibalt: A Decenarian fraa from the Concent of Saunt Edhar and one of Erasmas's friends. The estranged son of a religious official, he seeks to reconcile religion with theorics. Lio: A Decenarian fraa from the Concent of Saunt Edhar and one of Erasmas's friends. He's known as an absent-minded eccentric and is interested in military history, Vale-lore (martial arts), and unusual gardening techniques. He leads the space mission to destroy the alien weapon. Jesry: A Decenarian fraa from the Concent of Saunt Edhar and one of Erasmas's friends. Unlike Erasmas, Jesry comes from a prosperous family, and is bored with the routine of mathic life preceding the arrival of the aliens. He becomes famous for going into space with the Warden of Heaven (a religious leader of the Sæcular Power) to investigate the alien ship. Ala: A Decenarian suur from the Concent of Saunt Edhar. She becomes a major organizer of the Convox, and later, the Arbran resistance.
Billerica, Kent: A deserted town adjacent to the settlement of Court-up-Street by Port Lympne. Significantly, this is adjacent to a Roman Saxon Shore fort, as well as being on spring lines suitable for growing watercress Billerica Farm, near Upton Noble, Somerset: Although this farm might be named after the other Billericas, the site is also close to springs suitable for farming watercress. The Tudor antiquarian John Leland believed the already-abandoned Billerica in Kent was a variant of Bellocastrum, ‘fair castle’ in Latin. In Billericay, there is a Roman fort at Blunt's Wall Farm; likewise ‘Burh’ gives its name to Great Burstead. This suggests that a Romano-British place name was reused by the Anglo-Saxons following the end of Roman rule in Britain.
=== Health risks === Taking lithium salts has risks and side effects. Extended use of lithium to treat mental disorders has been known to lead to acquired nephrogenic diabetes insipidus. Lithium toxicity can affect the central nervous system and renal system and can be lethal at levels above 2.0 mmol/L. Over a prolonged period, lithium can accumulate in the principal cells of the collecting duct and interfere with antidiuretic hormone (ADH), which regulates the water permeability of principal cells in the collecting tubule. The medullary interstitium of the collecting duct system naturally has a high sodium concentration and attempts to maintain it. There is no known mechanism for cells to distinguish lithium ions from sodium ions, so damage to the kidney's nephrons may occur if lithium concentrations become too high as a result of dehydration, hyponatremia, an unusually low sodium diet, or certain drugs.
Sources: en.wikipedia.org
=== Earlier capitals === Bath, the oldest town in North Carolina, was the first nominal capital of the colony from 1705 until 1722, when Edenton took over the role. The colony had no permanent institutions of government until the new capital, New Bern, was established in 1743.
=== Progress === To measure the results, the Government also set goals that corresponded to these research projects. The goals include: completion of the immunoprophylaxis strategy, such as HBV vaccine, to decrease the incidence of HCC by more than 10%; identification of molecular biomarkers, and the creation of molecular-typing diagnostic kits for the prediction of the therapeutic response; the development of regimens to treat HBV; the identification of biomarkers to predict the aggressiveness of severe hepatitis B and the development of a kit for early diagnosis of liver cirrhosis; the identification of markers (biological and genomic, and small molecules) for early diagnosis and to predict recurrence and metastasis, and the development of new drugs for HCC, to increase the rate of early diagnosis by more than 20% and 5-year survival by more than 5%. The fight against HBV and its related disorders is now thought of as a long-term one by the health authorities.
=== Detection in body fluids === Drug detection in body fluids requires specific reference data from the target drug. A common pitfall in the detection of New Psychoactive Substances (NPS) is the lack of reference data available for spectrometers to identify the presence of structurally modified illicit substances. Another drug detection technique, immunoassay, relies on active antibodies to detect the target drug by selectivity. If the drug is structurally modified, the original antibodies will respond in a different fashion which will give false positive or negative results.
In hepatocellular carcinoma models, O-GlcNAc is associated with activating phosphorylation of HDAC1, which in turn regulates expression of the cell cycle regulator p21Waf1/Cip1 and cell motility regulator E-cadherin. OGT has been found to stabilize SREBP-1 and activate lipogenesis in breast cancer cell lines. This stabilization was dependent on the proteasome and AMPK. OGT knockdown resulted in decreased nuclear SREBP-1, but proteasomal inhibition with MG132 blocked this effect. OGT knockdown also increased the interaction between SREBP-1 and the E3 ubiquitin ligase FBW7. AMPK is activated by T172 phosphorylation upon OGT knockdown, and AMPK phosphorylates SREBP-1 S372 to inhibit its cleavage and maturation. OGT knockdown had a diminished effect on SREBP-1 levels in AMPK-null cell lines. In a mouse model, OGT knockdown inhibited tumor growth but SREBP-1 overexpression partly rescued this effect. These results contrast from those of a previous study which found that OGT knockdown/inhibition inhibited AMPK T172 phosphorylation and increased lipogenesis. In breast and prostate cancer cell lines, high levels of OGT and O-GlcNAc have been associated both in vitro and in vivo with processes associated with disease progression, e.g., angiogenesis, invasion, and metastasis. OGT knockdown or inhibition was found to downregulate the transcription factor FoxM1 and upregulate the cell-cycle inhibitor p27Kip1 (which is regulated by FoxM1-dependent expression of the E3 ubiquitin ligase component Skp2), causing G1 cell cycle arrest.
=== Special populations === Patients already suffering from debilitation are at a much higher risk of respiratory depression. Non-opioid analgesics should be considered in this population. Elderly patients are much more sensitive to adverse effects such as falls, cognitive impairment and constipation, and should be monitored for such. Decreased renal function associated with aging leads to decreased clearance of the drug, resulting in narrow therapeutic windows and increasing the danger of overdose. If oxymorphone is absolutely indicated, smaller initial doses should be started for this population. There is a risk of neonatal withdrawal symptom in the newborn if pregnant women take oxymorphone for a prolonged period. Oxymorphone crosses the placenta and holds risk of birth defects, poor fetal growth, stillbirth, and preterm delivery. The children of mothers who are physically dependent on oxymorphone have a higher risk of similar dependence. Due to these severe risks, oxymorphone is highly discouraged among this population. The amount of transfer of oxymorphone into the breast milk is not known and women are cautioned to weigh the risks and benefits before breastfeeding while on this medication.
Sources: en.wikipedia.org
The current supply is based on a semisynthetic process developed by PharmaMar starting from safracin B, a chemical obtained by fermentation of the bacterium Pseudomonas fluorescens. PharmaMar entered into an agreement with Johnson & Johnson to market the compound outside Europe.
==== Universities, libraries, and academic research ==== Conversely, academia and libraries are concerned that narrow copyright and TDM exceptions restrict access to research for AI training. Major academic publishers restrict universities from using subscribed databases for AI training without permission, while simultaneously selling access to commercial AI developers. This creates a "triple payment" problem where publicly funded research is paid for multiple times by universities. Advocacy groups argue publishers use contract law to override statutory rights, hindering the UK's sovereign AI research capacity. In response, Jisc advised universities to resist restrictive AI clauses in publisher licences. The UK's TDM exception is limited to non-commercial research, which groups like Knowledge Rights 21 argue will hobble the UK's "AI for Science" strategy.
To date, medical psychologists (prescribing psychologists) may prescribe psychotropic medications in Guam, Iowa, Idaho, Illinois, New Mexico, Louisiana, Colorado, Utah, Vermont, the Public Health Service, the Indian Health Service, and the United States Military. In contrast, psychiatrists are legally authorized to prescribe psychotropic medications in all states of the U.S. and in all provinces of Canada. However, psychiatrists are not usually involved in psychometric assessment. In education, clinical psychologists attend a graduate institution and have a Doctor of Philosophy (Ph.D.) or a Doctor of Psychology (Psy.D.) degree, usually following both an undergraduate and master's degree in Psychology or a related discipline. Conversely, psychiatrists complete their studies at a medical school and hold a medical degree (M.D.), Bachelor of Medicine, Bachelor of Surgery (with additional post-graduate training), or an osteopathic degree and the (D.O.) which is only available in the United States. Due to their scientist-practitioner model of training, clinical psychologists have more advanced research knowledge and skills, including advanced training in statistics, compared with standard psychiatric training.
== Further reading == Habibi, N; Kamaly, N; Memic, A; Shafiee, H (2016). "Self-assembled peptide-based nanostructures: Smart nanomaterials toward targeted drug delivery". Nano Today. 11 (1): 41–60. doi:10.1016/j.nantod.2016.02.004. PMC 4834907. PMID 27103939.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.